- Report
- May 2024
- 140 Pages
Global
From €6071EUR$6,499USD£5,136GBP
- Report
- June 2024
- 200 Pages
Global
From €7427EUR$7,950USD£6,283GBP
- Report
- June 2024
- 200 Pages
Global
From €7427EUR$7,950USD£6,283GBP
- Report
- January 2022
- 60 Pages
Global
From €3690EUR$3,950USD£3,122GBP
- Report
- January 2022
- 60 Pages
Global
From €3690EUR$3,950USD£3,122GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1168EUR$1,250USD£988GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1168EUR$1,250USD£988GBP
- Report
- August 2024
- 83 Pages
Global
From €3500EUR$4,013USD£3,065GBP
- Report
- May 2022
- 70 Pages
Global
From €1868EUR$2,000USD£1,581GBP
Pyelonephritis is a type of kidney infection that is caused by bacteria. It is a serious condition that can lead to permanent kidney damage if left untreated. Treatment for pyelonephritis typically involves antibiotics, and in some cases, hospitalization. Liver and kidney disorders drugs are used to treat a variety of conditions, including pyelonephritis. These drugs can help reduce inflammation, reduce pain, and improve kidney function. Commonly prescribed drugs for pyelonephritis include cephalosporins, fluoroquinolones, and aminoglycosides.
The pyelonephritis drug market is a subset of the larger liver and kidney disorders drugs market. It is a rapidly growing market, driven by the increasing prevalence of kidney infections and the need for effective treatments. The market is highly competitive, with a number of companies offering a variety of drugs for the treatment of pyelonephritis.
Some of the major companies in the pyelonephritis drug market include Pfizer, Merck, GlaxoSmithKline, AstraZeneca, and Novartis. These companies offer a range of drugs for the treatment of pyelonephritis, including cephalosporins, fluoroquinolones, and aminoglycosides. Show Less Read more